Jed Kaminetsky
Overview
Explore the profile of Jed Kaminetsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Copelan O, Moss J, Freedman S, Coutinho K, Elterman D, Marotte J, et al.
J Sex Med
. 2025 Jan;
PMID: 39829245
Background: The Optilume benign prostatic hyperplasia (BPH) catheter system is a novel minimally invasive paclitaxel-coated dilation system that has demonstrated substantial and durable results in urinary flow and symptoms. Aim:...
2.
Miner M, Wang C, Kaminetsky J, Khera M, Goldstein I, Carson 3rd C, et al.
Andrology
. 2024 Sep;
PMID: 39252657
Background: Testosterone deficiency results from insufficient testosterone production. Testosterone therapy may require dose titration to reach eugonadal serum testosterone concentrations. Objective: The primary objective was the efficacy of oral testosterone...
3.
Chamie K, Chang S, Kramolowsky E, Gonzalgo M, Agarwal P, Bassett J, et al.
NEJM Evid
. 2024 Feb;
2(1):EVIDoa2200167.
PMID: 38320011
BACKGROUND: Patients with Bacillus Calmette–Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC) have limited treatment options. The immune cell–activating interleukin-15 (IL-15) superagonist Nogapendekin alfa inbakicept (NAI), also known as N-803, may act...
4.
Kaplan S, Moss J, Freedman S, Coutinho K, Wu N, Efros M, et al.
J Urol
. 2023 Aug;
210(3):500-509.
PMID: 37555604
Purpose: The Optilume BPH Catheter System is a novel drug/device combination minimally invasive surgical therapy for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. The PINNACLE...
5.
Kaplan S, Moss J, Freedman S, Coutinho K, Wu N, Efros M, et al.
J Urol
. 2023 Aug;
210(3):509.
PMID: 37555602
No abstract available.
6.
Honig S, Gittelman M, Kaminetsky J, Wang C, Amory J, Rohowsky N, et al.
J Sex Med
. 2022 Oct;
19(12):1750-1758.
PMID: 36272969
Background: Long-term data evaluating the efficacy and safety of oral testosterone undecanoate (oral TU; JATENZO) in adult hypogonadal men provides important information for healthcare professionals who prescribe testosterone replacement therapy...
7.
Elterman D, Alshak M, Martinez Diaz S, Shore N, Gittleman M, Motola J, et al.
J Endourol
. 2022 Sep;
37(1):74-79.
PMID: 36070450
To document the effect of the temporarily implanted nitinol device (iTind; Medi-Tate Ltd, Israel) on sexual function from a multicenter, randomized, single-blinded, sham-controlled trial. Men were randomized 2:1 between iTind...
8.
McVary K, Gittelman M, Goldberg K, Patel K, Shore N, Levin R, et al.
J Urol
. 2021 Jun;
206(3):724.
PMID: 34077266
No abstract available.
9.
McVary K, Gittelman M, Goldberg K, Patel K, Shore N, Levin R, et al.
J Urol
. 2021 Apr;
206(3):715-724.
PMID: 33872051
Purpose: We present final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor therapy (Rezūm™) for treatment of moderate to severe lower urinary tract symptoms due to...
10.
Swerdloff R, Wang C, White W, Kaminetsky J, Gittelman M, Longstreth J, et al.
J Clin Endocrinol Metab
. 2020 May;
105(8).
PMID: 32382745
Context: A novel formulation of oral testosterone (T) undecanoate (TU) was evaluated in a phase 3 clinical trial. Objective: Determine efficacy, short-term safety, and alignment of new oral TU formulation...